Who
Ralph Smalling
Head of Regulatory
Company insider
Files Form 4 as: Head of Regulatory, Genelux.
In numbers
- Trades disclosed
- 29
- Buys
- 1
- Sells
- 11
- Bought
- $0
- Sold
- $46K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Aug 2023
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $563192 at $2.93 | filing |
| 3 Jun 2026filed 4 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $563192 at $2.93 | filing |
| 11 May 2026filed 12 May 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $804270 at $2.98 | filing |
| 11 May 2026filed 12 May 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $805270 at $2.98 | filing |
| 25 Mar 2026filed 26 Mar 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $602240 at $2.51 | filing |
| 25 Mar 2026filed 26 Mar 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $602240 at $2.51 | filing |
| 24 Mar 2026filed 26 Mar 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $835345 at $2.42 | filing |
| 24 Mar 2026filed 26 Mar 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $835345 at $2.42 | filing |
| 5 Dec 2025filed 9 Dec 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $774165 at $4.69 | filing |
| 17 Nov 2025filed 9 Dec 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $1,842343 at $5.37 | filing |
| 3 Sep 2025filed 9 Dec 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $1,949580 at $3.36 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,333 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,333 | filing |
| 1 Sep 2025filed 3 Sep 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 Aug 2025filed 29 Aug 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,770 at $0.00 | filing |
| 27 Aug 2025filed 29 Aug 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —26,230 at $0.00 | filing |
| 21 Aug 2025filed 9 Dec 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $4,1801,244 at $3.36 | filing |
| 12 May 2025filed 13 May 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $3,6761,259 at $2.92 | filing |
| 14 Mar 2025filed 17 Apr 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —4,172 at $0.00 | filing |
| 18 Dec 2024filed 20 Dec 2024 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,100 at $0.00 | filing |
News
Genelux (NASDAQ:GNLX) Upgraded at Wall Street ZenGNLX · dailypolitical.com · 23 Oct 2026Head-To-Head Analysis: Foghorn Therapeutics (NASDAQ:FHTX) vs. Genelux (NASDAQ:GNLX)GNLX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Ralph Smalling; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.